Literature DB >> 6328991

Cerebral blood flow in patients with congestive heart failure treated with captopril.

O B Paulson, J O Jarden, J Godtfredsen, S Vorstrup.   

Abstract

The effect of captopril on cerebral blood flow was studied in five patients with severe congestive heart failure and in five control subjects. Cerebral blood flow was measured by inhalation of 133xenon and registration of its uptake and washout from the brain by single photon emission computer tomography. In addition, cerebral (internal jugular) venous oxygen tension was determined in the controls. The measurements were made before and 15, 60, and 180 minutes after a single oral dose of captopril (6.25 mg in patients with congestive heart failure and 25 mg in controls). Despite a marked decrease in blood pressure, cerebral blood flow increased slightly in the patients with severe congestive heart failure. When a correction was applied to take account of a change in arterial carbon dioxide tension, however, cerebral blood flow was unchanged after captopril administration even in patients with the greatest decrease in blood pressure, in whom a decrease in cerebral blood flow might have been expected. In the controls, blood pressure was little affected by captopril, whereas a slight, but not statistically significant, decrease in cerebral blood flow was observed. The cerebral venous oxygen tension decreased concomitantly.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328991     DOI: 10.1016/0002-9343(84)90892-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  The heart-brain connection: mechanistic insights and models.

Authors:  K Ritz; M A van Buchem; M J Daemen
Journal:  Neth Heart J       Date:  2013-02       Impact factor: 2.380

Review 2.  Pumps, aqueducts, and drought management: vascular physiology in vascular cognitive impairment.

Authors:  Randolph S Marshall; Ronald M Lazar
Journal:  Stroke       Date:  2010-12-09       Impact factor: 7.914

3.  Reduced regional cerebral blood flow in patients with heart failure.

Authors:  Bhaswati Roy; Mary A Woo; Danny J J Wang; Gregg C Fonarow; Ronald M Harper; Rajesh Kumar
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

Review 4.  Angiotensin converting enzyme inhibitors versus digoxin for the treatment of congestive heart failure.

Authors:  I Crozier; H Ikram
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 5.  Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.

Authors:  W J Remme
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 6.  The use of angiotensin-converting enzyme inhibitors in congestive heart failure.

Authors:  J L Rouleau; C Juneau; J de Champlain
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

7.  Angiotensin converting enzyme inhibition improves cerebrovascular control during exercise in male rats with heart failure.

Authors:  Alec L E Butenas; Trenton D Colburn; Dryden R Baumfalk; Carl J Ade; K Sue Hageman; Steven W Copp; David C Poole; Timothy I Musch
Journal:  Respir Physiol Neurobiol       Date:  2021-01-06       Impact factor: 1.931

Review 8.  Heart failure and Alzheimer's disease.

Authors:  P Cermakova; M Eriksdotter; L H Lund; B Winblad; P Religa; D Religa
Journal:  J Intern Med       Date:  2014-08-01       Impact factor: 8.989

9.  Tumor Necrosis Factor-α Underlies Loss of Cortical Dendritic Spine Density in a Mouse Model of Congestive Heart Failure.

Authors:  Anja Meissner; Naomi P Visanji; M Abdul Momen; Rui Feng; Beverly M Francis; Steffen-Sebastian Bolz; Lili-Naz Hazrati
Journal:  J Am Heart Assoc       Date:  2015-05-06       Impact factor: 5.501

Review 10.  Heart failure and cognitive impairment: challenges and opportunities.

Authors:  George A Heckman; Christopher J Patterson; Catherine Demers; Joye St Onge; Irene D Turpie; Robert S McKelvie
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.